Alligator Bioscience Receives FDA Orphan Drug Designation for Mitazalimab in Pancreatic Cancer
Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that the U.S. Food and Drug Administration (FDA) has granted O ...
Alligator Bioscience Announces FDA Authorization to Initiate Mitazalimab OPTIMIZE-2 Phase 2 Trial in Urothelial Carcinoma
OPTIMIZE-2 is a Phase 2 study to assess the safety and efficacy of mitazalimab in combination with a PD-1 inhibitor in patients affected by ...
Alligator Bioscience Announces KOL Interview on Mitazalimab and the Positive Interim Results from the OPTIMIZE-1 Phase 2 Trial in Pancreatic Cancer
Interview features OPTIMIZE-1 Principal Investigator Jean-Luc Van Laethem from Erasmus Hospital and Alligator CMO Sumeet Ambarkhane OPTIMIZE ...
Alligator Bioscience Announces Positive Interim Results from Mitazalimab OPTIMIZE-1 Phase 2 Trial in Pancreatic Cancer Exceeding 50% Objective Response Rate
52% Objective Response Rate in pre-planned interim efficacy analysis of mitazalimab combined with mFOLFIRINOX in 1st line metastatic pancrea ...
Alligator Bioscience Announces Publication Highlighting Phase 1 Mitazalimab Data in Solid Tumors in Peer-Reviewed Journal “Investigational New Drugs”
Data confirm mitazalimab's manageable safety profile via a thorough dose-escalation approach via intravenous administration Pharmacokin ...
Data presented on mitazalimab and ATOR-1017 in Two Poster Presentations at SITC Annual Meeting 2022 – November 8-12, 2022
Mitazalimab data show the CD40 agonist induces strong immune responses in patients with advanced stage solid tumors and further strengthens ...